vorinostat has been researched along with Nerve Degeneration in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We use a Drosophila Huntington's disease model to establish dose regimens and protocols to assess the effectiveness of drug combinations used at low threshold concentrations." | 1.33 | Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila. ( Agrawal, N; Apostol, BL; Bodai, L; Chang, LW; Chiang, AS; Marsh, JL; Pallos, J; Slepko, N; Thompson, LM, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alam, MS | 1 |
| Getz, M | 1 |
| Haldar, K | 1 |
| Kidd, SK | 1 |
| Schneider, JS | 1 |
| Agrawal, N | 1 |
| Pallos, J | 1 |
| Slepko, N | 1 |
| Apostol, BL | 1 |
| Bodai, L | 1 |
| Chang, LW | 1 |
| Chiang, AS | 1 |
| Thompson, LM | 1 |
| Marsh, JL | 1 |
3 other studies available for vorinostat and Nerve Degeneration
| Article | Year |
|---|---|
Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; beta-Cyclodextrins; Blood-Brain Barrier; Disease Models, | 2016 |
Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition.
Topics: 1-Methyl-4-phenylpyridinium; Acetylation; Analysis of Variance; Animals; Apoptosis; Butyric Acid; Ce | 2010 |
Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.
Topics: Amides; Animals; Benzoquinones; Disease Models, Animal; Drosophila; Drug Therapy, Combination; Femal | 2005 |